Europe Hyaluronidase Market Size & Outlook, 2023-2030

The hyaluronidase market in Europe is expected to reach a projected revenue of US$ 455.6 million by 2030. A compound annual growth rate of 8.4% is expected of Europe hyaluronidase market from 2024 to 2030.
Revenue, 2023 (US$M)
$258.4
Forecast, 2030 (US$M)
$455.6
CAGR, 2024 - 2030
8.4%
Report Coverage
Europe

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe hyaluronidase market, 2018-2030 (US$M)

Europe hyaluronidase market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe hyaluronidase market highlights

  • The Europe hyaluronidase market generated a revenue of USD 258.4 million in 2023.
  • The market is expected to grow at a CAGR of 8.4% from 2024 to 2030.
  • In terms of segment, animal-derived hyaluronidase was the largest revenue generating type in 2023.
  • Animal-derived Hyaluronidase is the most lucrative type segment registering the fastest growth during the forecast period.


Europe data book summary

Market revenue in 2023USD 258.4 million
Market revenue in 2030USD 455.6 million
Growth rate8.4% (CAGR from 2023 to 2030)
Largest segmentAnimal-derived hyaluronidase
Fastest growing segmentAnimal-derived Hyaluronidase
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationAnimal-derived Hyaluronidase
Key market players worldwideBausch & Lomb Corp, The Cooper Companies Inc, Sun Pharmaceutical Industries, STEMCELL Technologies, Amphastar Pharmaceuticals Inc, Prima Pharm, Halozyme Therapeutics, Shreya Life Sciences


Other key industry trends

  • In terms of revenue, Europe region accounted for 26.2% of the global hyaluronidase market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 382.0 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hyaluronidase Market Companies

Name Profile # Employees HQ Website
Shreya Life Sciences View profile 1001-5000 Mumbai, Maharashtra, India, Asia http://www.shreya.co.in/
Halozyme Therapeutics View profile 101-250 San Diego, California, United States, North America http://www.halozyme.com
Prima Pharm View profile 51-100 San Diego, California, United States, North America http://primapharm.net/
Amphastar Pharmaceuticals Inc View profile - - -
STEMCELL Technologies View profile 501-1000 Vancouver, British Columbia, Canada, North America https://www.stemcell.com
Sun Pharmaceutical Industries View profile 10001+ Mumbai, Maharashtra, India, Asia http://www.sunpharma.com
The Cooper Companies Inc View profile 15000 6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, United States, 94583 https://www.coopercos.com
Bausch & Lomb Corp View profile 13300 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4 https://www.bausch.com

Europe hyaluronidase market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hyaluronidase market will help companies and investors design strategic landscapes.


Animal-derived hyaluronidase was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Europe hyaluronidase market based on animal-derived hyaluronidase covering the revenue growth of each sub-segment from 2018 to 2030.


Rising incorporation of hyaluronidase in various drug delivery technologies has encouraged local manufacturers to invest in the development of novel hyaluronidase products. For instance, in March 2019, ALTEOGEN, Inc. received a patent for its subcutaneous formulation of trastuzumab biosimilar that incorporates human hyaluronidase for the treatment of breast cancer.

Alteogen announced that it has plans to file additional Patent Cooperation Treaty and patent applications in 12 countries including Europe. This patent application is expected to allow the company to monopolize the European market for subcutaneous version of biosimilar trastuzumab.

Moreover, guidelines issued by multiple private and public entities for the use of hyaluronidase in esthetic procedures ensure efficient regulation and management of hyaluronidase in Europe.

Reasons to subscribe to Europe hyaluronidase market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe hyaluronidase market databook

  • Our clientele includes a mix of hyaluronidase market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe hyaluronidase market , including forecasts for subscribers. This continent databook contains high-level insights into Europe hyaluronidase market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online